niclosamide has been researched along with Lung Neoplasms in 15 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The potency of niclosamide on breast cancer was assessed in vitro and in vivo." | 5.40 | The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. ( Li, D; Liu, L; Song, X; Wang, N; Wei, Y; Xia, Y; Xiong, Y; Yan, Y; Ye, T; Yu, L; Zeng, J; Zhang, L; Zhu, Y, 2014) |
| "Niclosamide is an antihe-minthic drug that has shown cytotoxic effects on non-small cell lung carcinoma (NSCLC) cells." | 1.56 | Antihelminthic Niclosamide Induces Autophagy and Delayed Apoptosis in Human Non-small Lung Cancer Cells ( Chai, WH; Chan, PC; Chao, YH; Chen, CH; Li, YR; Lin, CH; Lin, SH, 2020) |
| " This technique could help in improving bioavailability of drug, hence reducing the need for high dosages and signifying a novel paradigm for future clinical applications." | 1.56 | Autophagy-Inducing Inhalable Co-crystal Formulation of Niclosamide-Nicotinamide for Lung Cancer Therapy. ( Khan, R; Kumar, A; Ray, E; Sharma, A; Shukla, R; Vaghasiya, K; Verma, RK, 2020) |
| "Lung cancer is the most commonly diagnosed cancer worldwide with a high mortality rate." | 1.51 | Effective and new potent drug combination: Histone deacetylase and Wnt/β-catenin pathway inhibitors in lung carcinoma cells. ( Akgun, O; Ari, F; Erkisa, M, 2019) |
| "Lung cancer is a leading cause of cancer-associated mortality worldwide." | 1.48 | Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc. ( Jiang, D; Li, H; Li, J; Xiang, M; Xu, Z; Yang, D; Yang, J; Yu, Y; Yu, Z; Zhou, H; Zuo, Y, 2018) |
| "Biotin-decorated PMM were internalized more efficiently than non-targeted PMM in A549 lung cancer cells, while very low internalization was found in NHI3T3 normal fibroblasts." | 1.43 | Biotin-targeted Pluronic(®) P123/F127 mixed micelles delivering niclosamide: A repositioning strategy to treat drug-resistant lung cancer cells. ( Budillon, A; Caetano, W; Hioka, N; Milone, MR; Pagliara, V; Pellosi, DS; Pucci, B; Quaglia, F; Russo, A; Russo, G; Ungaro, F, 2016) |
| "The potency of niclosamide on breast cancer was assessed in vitro and in vivo." | 1.40 | The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. ( Li, D; Liu, L; Song, X; Wang, N; Wei, Y; Xia, Y; Xiong, Y; Yan, Y; Ye, T; Yu, L; Zeng, J; Zhang, L; Zhu, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erturk, E | 1 |
| Onur, OE | 1 |
| Aydin, I | 1 |
| Akgun, O | 2 |
| Coskun, D | 1 |
| Ari, F | 2 |
| Hochmair, M | 1 |
| Rath, B | 1 |
| Klameth, L | 1 |
| Ulsperger, E | 1 |
| Weinlinger, C | 1 |
| Fazekas, A | 1 |
| Plangger, A | 1 |
| Zeillinger, R | 1 |
| Hamilton, G | 1 |
| Luo, F | 1 |
| Luo, M | 1 |
| Rong, QX | 1 |
| Zhang, H | 1 |
| Chen, Z | 1 |
| Wang, F | 1 |
| Zhao, HY | 1 |
| Fu, LW | 1 |
| Chai, WH | 1 |
| Li, YR | 1 |
| Lin, SH | 1 |
| Chao, YH | 1 |
| Chen, CH | 1 |
| Chan, PC | 1 |
| Lin, CH | 1 |
| Ray, E | 1 |
| Vaghasiya, K | 1 |
| Sharma, A | 1 |
| Shukla, R | 1 |
| Khan, R | 1 |
| Kumar, A | 1 |
| Verma, RK | 1 |
| Hilfenhaus, G | 1 |
| Mompeón, A | 1 |
| Freshman, J | 1 |
| Prajapati, DP | 1 |
| Hernandez, G | 1 |
| Freitas, VM | 1 |
| Ma, F | 1 |
| Langenbacher, AD | 1 |
| Mirkov, S | 1 |
| Song, D | 1 |
| Cho, BK | 1 |
| Goo, YA | 1 |
| Pellegrini, M | 1 |
| Chen, JN | 1 |
| Damoiseaux, R | 1 |
| Iruela-Arispe, ML | 1 |
| He, X | 1 |
| Li, M | 1 |
| Ye, W | 1 |
| Zhou, W | 1 |
| Kim, MO | 1 |
| Choe, MH | 1 |
| Yoon, YN | 1 |
| Ahn, J | 1 |
| Yoo, M | 1 |
| Jung, KY | 1 |
| An, S | 1 |
| Hwang, SG | 1 |
| Oh, JS | 1 |
| Kim, JS | 1 |
| Zuo, Y | 1 |
| Yang, D | 1 |
| Yu, Y | 1 |
| Xiang, M | 1 |
| Li, H | 1 |
| Yang, J | 1 |
| Li, J | 1 |
| Jiang, D | 1 |
| Zhou, H | 1 |
| Xu, Z | 1 |
| Yu, Z | 1 |
| Yuquan, B | 1 |
| Hexiao, T | 1 |
| Laiyi, W | 1 |
| Gaofeng, P | 1 |
| Xuefeng, Z | 1 |
| Ming, X | 1 |
| Yanhong, W | 1 |
| Li, Z | 1 |
| Jinping, Z | 1 |
| Erkisa, M | 1 |
| You, S | 1 |
| Li, R | 1 |
| Park, D | 1 |
| Xie, M | 1 |
| Sica, GL | 1 |
| Cao, Y | 1 |
| Xiao, ZQ | 1 |
| Deng, X | 1 |
| Ye, T | 1 |
| Xiong, Y | 1 |
| Yan, Y | 1 |
| Xia, Y | 1 |
| Song, X | 1 |
| Liu, L | 2 |
| Li, D | 1 |
| Wang, N | 1 |
| Zhang, L | 1 |
| Zhu, Y | 1 |
| Zeng, J | 1 |
| Wei, Y | 1 |
| Yu, L | 1 |
| Stewart, RL | 1 |
| Carpenter, BL | 1 |
| West, DS | 1 |
| Knifley, T | 1 |
| Wang, C | 1 |
| Weiss, HL | 1 |
| Gal, TS | 1 |
| Durbin, EB | 1 |
| Arnold, SM | 1 |
| O'Connor, KL | 1 |
| Chen, M | 1 |
| Russo, A | 1 |
| Pellosi, DS | 1 |
| Pagliara, V | 1 |
| Milone, MR | 1 |
| Pucci, B | 1 |
| Caetano, W | 1 |
| Hioka, N | 1 |
| Budillon, A | 1 |
| Ungaro, F | 1 |
| Russo, G | 1 |
| Quaglia, F | 1 |
15 other studies available for niclosamide and Lung Neoplasms
| Article | Year |
|---|---|
Targeting the epithelial-mesenchymal transition (EMT) pathway with combination of Wnt inhibitor and chalcone complexes in lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Chalcone; Chalcones; Epithelial-Mes | 2023 |
Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines.
Topics: Antigens, CD; Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Humans; Lung Neop | 2020 |
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antinematodal Agents; Apoptosis; B7-H1 Antigen; Carcinoma, Non-Smal | 2019 |
Antihelminthic Niclosamide Induces Autophagy and Delayed Apoptosis in Human Non-small Lung Cancer Cells
Topics: A549 Cells; Adenosine Triphosphate; Adenylate Kinase; Animals; Apoptosis; Autophagy; Carcinoma, Non- | 2020 |
Autophagy-Inducing Inhalable Co-crystal Formulation of Niclosamide-Nicotinamide for Lung Cancer Therapy.
Topics: Administration, Inhalation; Autophagy; Calorimetry, Differential Scanning; Crystallization; Desiccat | 2020 |
A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier.
Topics: Animals; Cell Communication; Cell Line, Tumor; Cell Proliferation; Colforsin; Drug Screening Assays, | 2021 |
Discovery of degradable niclosamide derivatives able to specially inhibit small cell lung cancer (SCLC).
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Drug | 2021 |
Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Topics: Anthelmintics; Antinematodal Agents; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; | 2017 |
Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cisplatin; | 2018 |
Interaction between epidermal growth factor receptor and interleukin-6 receptor in NSCLC progression.
Topics: A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Progression; ErbB | 2019 |
Effective and new potent drug combination: Histone deacetylase and Wnt/β-catenin pathway inhibitors in lung carcinoma cells.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Ce | 2019 |
Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer.
Topics: Apoptosis; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Humans; Janus Kinase 2; Lung Neoplas | 2014 |
The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model.
Topics: Animals; Anthelmintics; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell M | 2014 |
S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell | 2016 |
Biotin-targeted Pluronic(®) P123/F127 mixed micelles delivering niclosamide: A repositioning strategy to treat drug-resistant lung cancer cells.
Topics: A549 Cells; Animals; Antineoplastic Agents; Biotin; Cell Survival; Dose-Response Relationship, Drug; | 2016 |